The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease
2012
Parkinson’s disease (PD) is a progressive, chronic disease characterized by
dyskinesia, rigidity, instability, and tremors. The disease is defined by the presence of
Lewy bodies, which primarily consist of aggregated α-
synucleinprotein, and is accompanied by the loss of
monoaminergicneurons. Current therapeutic strategies only give symptomatic relief of motor impairment and do not address the underlying
neurodegeneration. Hence, we have identified CuII(atsm) as a potential therapeutic for PD. Drug administration to four different
animal modelsof PD resulted in improved motor and cognition function, rescued nigral cell loss, and improved dopamine metabolism. In vitro, this compound is able to inhibit the effects of
peroxynitrite-driven toxicity, including the formation of nitrated α-
synucleinoligomers. Our results show that CuII(atsm) is effective in reversing parkinsonian defects in
animal modelsand has the potential to be a successful treatment of PD.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
108
References
108
Citations
NaN
KQI